Response to the letter titled "Analysis of semaglutide's effect on Alzheimer's disease risk".
作者信息
Xu Rong
机构信息
Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
出版信息
Alzheimers Dement. 2025 Feb;21(2):e14509. doi: 10.1002/alz.14509. Epub 2025 Jan 14.
Abstract
摘要
相似文献
1
Response to the letter titled "Analysis of semaglutide's effect on Alzheimer's disease risk".对题为“司美格鲁肽对阿尔茨海默病风险的影响分析”的信件的回复。
Alzheimers Dement. 2025 Feb;21(2):e14509. doi: 10.1002/alz.14509. Epub 2025 Jan 14.
2
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
3
Response to the letter titled reply to "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".对题为《司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟》的信件的回复
Alzheimers Dement. 2025 Feb;21(2):e14611. doi: 10.1002/alz.14611.
4
Analysis of semaglutide's effect on Alzheimer's disease risk.
Alzheimers Dement. 2025 Feb;21(2):e14462. doi: 10.1002/alz.14462. Epub 2024 Dec 31.
5
Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.在 2 型糖尿病患者中，司美格鲁肽与烟草使用障碍的关联：使用真实世界数据的目标试验模拟。
Ann Intern Med. 2024 Aug;177(8):1016-1027. doi: 10.7326/M23-2718. Epub 2024 Jul 30.
6
Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways.超越糖尿病：司美格鲁肽通过神经炎症途径在调节情绪障碍中的作用。
Cell Mol Neurobiol. 2025 Mar 10;45(1):22. doi: 10.1007/s10571-025-01534-4.
7
Unlocking the Potential: Semaglutide's Impact on Alzheimer's and Parkinson's Disease in Animal Models.释放潜力：司美格鲁肽在动物模型中对阿尔茨海默病和帕金森病的影响
Curr Issues Mol Biol. 2024 Jun 13;46(6):5929-5949. doi: 10.3390/cimb46060354.
8
Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.肥胖、心血管疾病与司美格鲁肽的潜在作用：SELECT试验的见解
Curr Probl Cardiol. 2024 Jan;49(1 Pt A):102060. doi: 10.1016/j.cpcardiol.2023.102060. Epub 2023 Aug 26.
9
Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.皮下司美格鲁肽对比安慰剂在肥胖、非糖尿病成人中的减重疗效：系统评价与荟萃分析。
Int J Clin Pharm. 2022 Aug;44(4):852-859. doi: 10.1007/s11096-022-01428-1. Epub 2022 Jun 17.
10
Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art.司美格鲁肽在心力衰竭和动脉粥样硬化性心血管疾病中的应用：当前的技术水平
Heart Fail Rev. 2025 Mar 31. doi: 10.1007/s10741-025-10506-1.
本文引用的文献
1
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
Zotero 插件